Company intelligence / Profile preview

RESprotect GmbH

Ownership: Private
Development stage: Phase 2

Overview

RESprotect GmbH develops drugs to prevent and treat chemotherapeutic and radiation therapy resistance. Its lead candidate, RP101, an orally administered small molecule, has shown promising results in improving survival rates for advanced pancreatic cancer patients when combined with standard chemotherapy. In two separate clinical studies, co-treatment approximately doubled median survival compared to chemotherapy alone. The compound appears well tolerated with no known side effects. The company regained North American rights for RP101 after a previous partnership lapsed and seeks strategic alliances for further development.

Therapeutic areas: Oncology
Modalities: small molecules (notably nucleoside analogues)
Industry: Biotech

Drug pipeline

6 assets

RP525

Preclinical

5 more assets in the full pipeline.

Request access →

Partnerships

Previously partnered with SciClone Pharmaceuticals Inc. (USA) for North America rights to RP101; currently seeking new partners globally after regaining those rights.

Beyond the preview

Go deeper on RESprotect GmbH.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RESprotect GmbH.

Explore the full profile